Vectura logo

VEC - Vectura News Story

164.8p -0.2  -0.1%

Last Trade - 17/09/21

Mid Cap
Market Cap £987.7m
Enterprise Value £913.3m
Revenue £190.6m
Position in Universe 447th / 1781

Vectura, Sandoz gets favourable ruling in inhaler packaging case against GSK

Fri 4th October, 2019 3:15pm
Oct 4 (Reuters) - Vectura Group  VEC.L  said on Friday a
British court had ruled in its and partner Sandoz's  NOVN.S 
favour over the packaging of a generic version of an inhaler
made by bigger rival GlaxoSmithKline  GSK.L .
    Vectura said the court dismissed all GSK claims related to
the packaging of AirFluSal Forspiro, which it developed in
partnership with Swiss drugmaker Novartis-owned Sandoz as a
branded copycat of GSK's asthma inhaler, Seretide Accuhaler.*:nRSD8575Oa 
    GSK, with which Vectura has partnerships, did not
immediately respond to a request for comment. Vectura and GSK
have slapped claims against each other over certain products and
    In May, a jury found that one of Vectura's U.S. patents was
infringed by the sale of three of GSK's Ellipta products in the
United States and Vectura was awarded $89.7 million in damages.*:nL3N22G0AA 
    Sandoz launched AirFluSal Forspiro in late 2015, following
which GSK filed a legal claim that Sandoz had used shades of
purple similar to Seretide's packaging to pass off AirFluSal
Forspiro as being related to GSK's product.      
    Forspiro is a dry powder inhaler developed by Vectura and
licensed to Sandoz for use with the AirFluSal product. 
    Seretide is a combination of two active ingredients that
make it easier to breathe and is sold by GSK in the UK in two
 one of which is the Seretide Accuhaler, which delivers the drug
as a dry powder.
    Vectura shares rose as much as 2.4% after the announcement.

 (Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun
 ((; Twitter: @pushkala_a; within
UK: +44 20 7542 1810, outside UK: +91 80 6749 6633;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.